

Change List for 2025 IDOH Policy and Procedure Manual for Reporting Facilities

(The manual is available at <http://www.in.gov/isdh/24035.htm>.)

07/30/2025

Item, Section, or Issue	Change
Chapter 1, A. Required References	<ul style="list-style-type: none"> Updated Grade Manual link to v3.1 (Oct 2023) Updated SSDI Manual link to v3.1
Chapter 1, B. Additional Resources	<ul style="list-style-type: none"> STORE Manual 2025 link added AJCC new version 9 for 2025 added, AJCC staging portal link added Removed CRMPP 3rd edition description
Chapter 1, D. Suspense System	<ul style="list-style-type: none"> Updated paragraph related to RMCDS suspense system instructions. No longer supported by IDOH.
Chapter 3, B. 2-Required cases	<ul style="list-style-type: none"> D. Updated to clarify Optic Glioma behavior /1 reporting N. added PTLD behavior change from /1 to /3 making it reportable 1/1/2025
Chapter 3, G. 2. Hospital Using Paper Forms	<ul style="list-style-type: none"> Updated contact email for Patrick Sweany
Chapter 4, B-Guidelines for Interpretation of Terminology	<ul style="list-style-type: none"> Added explanation for LI-RADS, BI-RADS, PI-RADS terminology.
Chapter 5, Overview	<ul style="list-style-type: none"> Updated last paragraph "Chapter 3, Section C" to "Section B"
Chapter 5, General Abstracting Instructions	<ul style="list-style-type: none"> 4. Removed RMCDS from list of abbreviations
Chapter 5, State Data Set	<ul style="list-style-type: none"> Added NAACCR 1172 & 1174 SSDI-Required
Chapter 5, SSDI	<ul style="list-style-type: none"> Added SSDI's NAACCR #1172 PTLD and #1174 PD-L1
Chapter 5, Phase I Radiation Treatment Modality	<ul style="list-style-type: none"> C. added: "For cases diagnosed prior to January 1, 2018, use code 07 Brachytherapy, NOS." Per STORE
Chapter 5, Chemotherapy	<ul style="list-style-type: none"> A. 10. Removed- "If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer." Per STORE
Chapter 5, Cancer Identification	<ul style="list-style-type: none"> Updated text field headers to match WebPlus text field headers (ie. Text-Dx Proc XRAY/Scans Substantiate Staging, Added more descriptors and clarifying remarks (text examples). Description of Treatment, Added more descriptors and clarifying remarks (text examples).
Chapter 5, Surgical Diagnostic and Staging Procedure	<ul style="list-style-type: none"> f. Added: "**Aspirations can be a biopsy (tissue) or cytology (cells). Code tissue biopsy to Surgical Diagnostic and Staging Procedures. Code cytology cell aspiration in Diagnostic Confirmation." Per STORE
Chapter 5, Date of First Course Treatment	<ul style="list-style-type: none"> added k. "If the first course of treatment plan changes due to an improvement in the tumor burden, the added treatment would still be considered first course. An example is palliative chemotherapy/radiation is recommended and administered per the first course treatment plan. Initially resection of primary tumor was contraindicated due to tumor size and location. Follow up imaging shows an improvement in tumor burden and treatment plan changed since tumor is now resectable to include surgery. Even though the primary tumor

	resection was not noted in the FCOT plan, the resection would be captured as first course of treatment since there was no progression of tumor. “ Per STORE
Chapter 5, Patient and Hospital Identification	<ul style="list-style-type: none"> Suspense Case, Retired field 1/1/2025 No longer relevant for ISCR software (now WebPlus)
Chapter 6, Corrections and Followup	<ul style="list-style-type: none"> Part I, E. Added WebPlus upload option.
Appendix A	<ul style="list-style-type: none"> Breast, Removed “For single primaries only, code removal of involved contralateral breast under the data item Surgical Procedure/Other Site or Surgical Procedure/Other Site at This Facility.” Per STORE
Appendix B	<ul style="list-style-type: none"> Reportable List: Added: PTLD behavior change 1/1/2025+ Removed “Desmoid Fibromatosis” from list, not reportable
Appendix F	<ul style="list-style-type: none"> Updated SEER Appendix C link, access to all years from main page Added Minimum Text Guidelines reference with links to text field descriptions within document
Appendix G	<ul style="list-style-type: none"> Colon (C18.0-C18.9) (01/01/2024)-removed B120 per STORE 2025
All uses of term “RMCDS” in document	<ul style="list-style-type: none"> Replaced with “WebPlus” as the ISCR abstracting software
All references to “paper abstracts”	<ul style="list-style-type: none"> “*ISCR will no longer accept paper abstracts beginning 1/1/2026” added

[ICD-O-3.2 Updates for 2025](#)

Post Transplant Lymphoproliferative Disorder (PTLD), formerly 9971/1. PTLD is now reportable as 9971/3